Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
145.10
+2.57 (1.80%)
At close: Sep 5, 2025, 4:00 PM
145.00
-0.10 (-0.07%)
After-hours: Sep 5, 2025, 7:50 PM EDT
Insmed Revenue
Insmed had revenue of $107.42M in the quarter ending June 30, 2025, with 18.90% growth. This brings the company's revenue in the last twelve months to $398.11M, up 21.15% year-over-year. In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth.
Revenue (ttm)
$398.11M
Revenue Growth
+21.15%
P/S Ratio
65.90
Revenue / Employee
$313,222
Employees
1,271
Market Cap
30.67B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
| Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
| Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
| Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
| Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
INSM News
- 1 day ago - Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 1 day ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 16 days ago - Insmed To Present at September Investor Conferences - PRNewsWire
- 17 days ago - Lung Disease-Focused Insmed 'Must-Own' Name For Investors - Benzinga
- 25 days ago - FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease - Benzinga
- 25 days ago - US FDA approves Insmed's lung disease drug - Reuters
- 25 days ago - FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease - PRNewsWire
- 4 weeks ago - Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript - Seeking Alpha